Skip to main content

SECRETION AND BINDING OF INSULIN-LIKE GROWTH FACTOR-I BY A HUMAN MEDULLARY-THYROID CARCINOMA CELL-LINE

Buy Article:

$42.00 + tax (Refund Policy)

The TT human medullary thyroid carcinoma cell line secretes a 7.5 kD species with insulin-like growth factor (IGF-I) immunoreactivity and HPLC mobility and expresses IGF-I mRNA. Conditioned medium also contained IGF-binding activity with a pattern of displacement of [I-125]-IGF-I characteristic of IGF binding proteins. Western ligand analysis and immunobloting with anti-IGFBP4 antiserum identified a 34 kD IGF-I binding species. Northern analysis identified a 2.1 kb IGFBP4 mRNA species. Cell surface binding of [I-125]-IGF-I identified Type I IGF receptors. TT cells constitute a useful model to study the IGF-I autocrine system in the transformed state.

Document Type: Research Article

Affiliations: VET ADM MED CTR,DEPT MED,DIV ENDOCRINOL & HYPERTENS,MED SERV 111W,10701 E BLVD,CLEVELAND,OH 44106. CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106.

Publication date: 01 June 1993

More about this publication?
  • The International Journal of Oncology provides an international forum for the publication of the latest, cutting-edge research in the broad area of oncology and cancer treatment. The journal accepts original high quality works and reviews on all aspects of oncology research including carcinogenesis, metastasis, epidemiology, chemotherapy and viral oncology. Through fair and efficient peer review, the journal is dedicated to publishing top tier research in the field, offering authors rapid publication as well as high standards of copy-editing and production. The International Journal of Oncology is published on a monthly basis in both print and early online.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content